Analyst Price Target is $27.00
▲ +656.30% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for IMARA in the last 3 months. The average price target is $27.00, with a high forecast of $42.00 and a low forecast of $12.00. The average price target represents a 656.30% upside from the last price of $3.57.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in IMARA.
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and Ã-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.